Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $188.00 by Analysts at UBS Group

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective hoisted by UBS Group from $173.00 to $188.00 in a research note released on Tuesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

SRPT has been the subject of a number of other reports. Royal Bank of Canada restated an outperform rating and set a $181.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 6th. BMO Capital Markets raised their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a report on Monday, June 24th. Leerink Partners raised their target price on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an outperform rating in a report on Monday, June 24th. Needham & Company LLC reiterated a buy rating and issued a $235.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, June 27th. Finally, Robert W. Baird lifted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a research note on Friday, June 21st. Three investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $187.39.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $125.69 on Tuesday. The stock has a market cap of $11.88 billion, a PE ratio of 1,142.64 and a beta of 0.81. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25. The stock has a fifty day simple moving average of $139.24 and a 200-day simple moving average of $132.69.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same period last year, the business posted ($0.27) EPS. Sarepta Therapeutics’s revenue for the quarter was up 38.9% on a year-over-year basis. Equities analysts anticipate that Sarepta Therapeutics will post 1.47 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In other news, EVP Ryan Edward Brown sold 38,957 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Ryan Edward Brown sold 38,957 shares of Sarepta Therapeutics stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now directly owns 17,129 shares in the company, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,801 shares of company stock valued at $8,399,586. Corporate insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SRPT. Capital International Investors increased its position in Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after buying an additional 2,917,797 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the period. Norges Bank acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $80,697,000. Bank of Nova Scotia acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $50,990,000. Finally, Avoro Capital Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 7.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after purchasing an additional 319,444 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.